Medical School, Sigmund Freud University, Vienna, Austria.
Department of Internal Medicine V with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Wolkersbergenstr. 1, 1130, Vienna, Austria.
Wien Med Wochenschr. 2023 Feb;173(1-2):15-20. doi: 10.1007/s10354-022-00981-8. Epub 2022 Nov 28.
In a retrospective study, we analyzed the prevalence of elevated C‑reactive protein (CRP) serum levels in 148 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory features. Normal, up to 10-fold, and more than 10-fold elevated CRP levels were found in 18%, 59%, and 23% of CMML patients, respectively. Using the CRP cutoff value of 10 mg/L of the widely used Glasgow score, high CRP values were associated with inferior survival (13 vs. 39 months, p = 0.014), which retained prognostic significance in multivariate analysis. High CRP values were associated with lower hemoglobin levels. The survival difference between patients with normal (< 5 mg/L) and elevated CRP levels persisted after exclusion of patients with clinical infection. These findings indicate that in CMML patients, the presence of an acute-phase reaction is associated with a poor outcome, independent of clinical infection.
在一项回顾性研究中，我们分析了 148 例慢性髓单核细胞白血病（CMML）患者中 C 反应蛋白（CRP）血清水平升高的发生率、其潜在的预后影响以及与实验室特征的潜在相关性。CMML 患者中分别有 18%、59%和 23%的患者 CRP 水平正常、升高 10 倍和升高 10 倍以上。使用广泛使用的格拉斯哥评分的 CRP 截断值 10mg/L，高 CRP 值与生存不良相关（13 个月 vs. 39 个月，p=0.014），在多变量分析中保留预后意义。高 CRP 值与较低的血红蛋白水平相关。在排除有临床感染的患者后，CRP 水平正常（<5mg/L）和升高患者之间的生存差异仍然存在。这些发现表明，在 CMML 患者中，急性期反应的存在与不良预后相关，与临床感染无关。
